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Caspase-2-mediated cell death is required for deleting
aneuploid cells
S Dawar1, Y Lim1, J Puccini1,2, M White3, P Thomas3, L Bouchier-Hayes4, DR Green5, L Dorstyn1,6 and S Kumar1,6
Caspase-2, one of the most evolutionarily conserved of the caspase family, has been implicated in maintenance of chromosomal
stability and tumour suppression. Caspase-2 deﬁcient (Casp2−/−) mice develop normally but show premature ageing-related traits
and when challenged by certain stressors, succumb to enhanced tumour development and aneuploidy. To test how caspase-2
protects against chromosomal instability, we utilized an ex vivo system for aneuploidy where primary splenocytes from Casp2−/−
mice were exposed to anti-mitotic drugs and followed up by live cell imaging. Our data show that caspase-2 is required for deleting
mitotically aberrant cells. Acute silencing of caspase-2 in cultured human cells recapitulated these results. We further generated
Casp2C320S mutant mice to demonstrate that caspase-2 catalytic activity is essential for its function in limiting aneuploidy. Our
results provide direct evidence that the apoptotic activity of caspase-2 is necessary for deleting cells with mitotic aberrations to
limit aneuploidy.
Oncogene (2017) 36, 2704–2714; doi:10.1038/onc.2016.423; published online 19 December 2016
INTRODUCTION
Genomic instability, one of the characteristic traits of tumour cells,
is often caused by chromosome missegregation or DNA errors
arising from replicative, oxidative or oncogenic stress.1,2 Genomic
instability can either arise from various structural lesions, such as
mutations, chromosomal deletions or translocations, or can result
from numerical alterations where cells lose or gain copies of whole
chromosomes (aneuploidy).3 As the most common chromosome
abnormality in humans, aneuploidy is the most common
chromosome abnormality in humans, is the cause of many
congenital birth defects and is found in the majority of solid
tumours.4 It is also considered a major underlying contributor to
cancer onset and prognosis. Aneuploidy arises from aberrant
mitotic events, including defects in centrosome number,
kinetochore-microtubule attachments, spindle-assembly check-
point (SAC), chromosome cohesion or telomeres.4
Aberrant mitotic arrest mechanisms normally trigger cell death
by apoptosis, which is sometimes referred to as mitotic
catastrophe.5,6 Apoptosis of cells carrying mitotic defects can be
induced by inhibition of DNA damage response and cell cycle
checkpoint genes. It has been shown to occur in both a
p53-dependent and independent manner, such as in Chk2
inhibited syncytia or in polo-like kinase 2 (Plk 2)-depleted cells.6
Inhibition of apoptosis can promote pre-mature mitotic exit
(mitotic slippage) and cell cycle progression without chromatid
segregation.7,8 If these aberrant cells are not removed, they can
accumulate and acquire additional mutations, a key mechanism
leading to aneuploidy, tumorigenesis and antimitotic drug
resistance.4,9,10
Caspase-2 is one of the most evolutionarily conserved members
of the caspase family. Caspase-2 is activated following a variety
of cellular insults (metabolic imbalance, DNA damage)11 and
activates other caspases to both initiate and amplify the apoptosis
signal.12 Recent data suggest that caspase-2-deﬁcient (Casp2−/−)
MEFs can readily escape senescence, rapidly immortalise in
culture13 and show enhanced sensitivity to transformation by
oncogenes.14,15 In addition, Casp2−/− MEFs are more resistant to
apoptosis induced by microtubule and spindle poisons16 and
show increased DNA damage following irradiation,13 suggesting
that Casp2 loss can promote survival of cells with damaged DNA.
Although they develop normally, previous studies have estab-
lished that Casp2−/− mice show enhanced susceptibility to
tumorigenesis promoted by EμMyc, MMTV/c-neu and K-Ras,14,17–20
increased lymphomagenesis in Atm−/− mice,21 and diethylnitrosamine-
mediated hepatocellular carcinoma,22 indicating a role for
caspase-2 as a tumour suppressor. A common feature of the
Casp2−/− tumours from these mouse models is increased
chromosomal instability and aneuploidy.13,14,18,19,21,22 These
observations suggest that caspase-2 can protect cells against
aneuploidy and tumorigenic potential. Some previous in vitro
observations suggest that caspase-2 has a role in mitotic
catastrophe.5 Caspase-2 phosphorylation by Cdk1–cyclin B1
complex has been implicated as one mechanism that can prevent
caspase-2 activation and cell death,12 thereby promoting mitotic
slippage. However, the molecular details that trigger caspase-2
activation during mitotic arrest are not clear, and it is not known if
this directly leads to aneuploidy and tumorigenic transformation.
It is also unclear whether aneuploidy seen in Casp2−/− tumours
and MEFs is a consequence of caspase-2 function in promoting
apoptosis of mitotically aberrant cells or due to other roles of
caspase-2 in cell cycle.
To address this key question, we established an ex vivo system
for aneuploidy using primary cells or used a human cell line
acutely depleted of caspase-2. Our data show an important role
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for caspase-2 in limiting aneuploidy by deleting chromosomally
unstable cells, at least in part via Bid-mediated apoptosis. We also
tested the importance of caspase-2 catalytic activity in deleting
chromosomally unstable cells by generating a Casp2C320S mutant
mouse. Our results demonstrate that in the absence of caspase-2
activity, cells with defective mitosis become multinucleated and
are able to survive long term. Our work establishes a critical role
for caspase-2 in the efﬁcient apoptotic removal of potentially
tumorigenic cells and provides a basis for the tumour suppressor
function of caspase-2.
RESULTS
Caspase-2 deﬁcient cells are a novel model of aneuploidy
To test how caspase-2 loss might lead to aneuploidy, we utilized a
cell system that can monitor aneuploidy directly using the PLK1
inhibitor BI 2536. PLK1 plays a critical role in centrosome
maturation in late G2/early prophase and is required for
establishment of the mitotic spindle.23,24 Inhibition of PLK1 has
been shown to cause aneuploidy followed by apoptosis of these
aneuploid cells.25 As mouse embryonic ﬁbroblasts (MEFs) are
highly unstable in culture and cannot be used for such
experiments, we established freshly isolated primary mouse
splenocytes in cell culture. These cells were stimulated to
proliferate by concanavalin A (ConA) for 3 days, supplemented
with IL-2 and then exposed to the PLK1 inhibitor BI 253626 (PLK1-I)
for up to 2 days. The cells were then analysed for viability and
aneuploidy by time-lapse microscopy before and after PLK1-I
washout (Figure 1a). Control experiments showed that freshly
isolated Casp2−/− splenocytes proliferated faster in culture
following stimulation with ConA (Supplementary Figure S1a). In
addition, while the cell cycle proﬁles of both WT and Casp2−/−
splenocytes in culture were indistinguishable, a signiﬁcantly
increased percentage of Casp2−/− splenocytes were able to cycle
through G2/M following PLK1-I-mediated mitotic arrest and drug
washout (Supplementary Figure S1b). Karyotypic analysis showed
that after several days in culture approximately 15% of both WT
and Casp2−/− cells had become aneuploid. However, following
PLK1 inhibition and inhibitor washout Casp2−/− splenocytes were
signiﬁcantly more aneuploid than the WT cells (Figure 1b and
Supplementary Figure S2a–b). To test if inhibition of caspase
activity is sufﬁcient to cause aneuploidy in WT splenocytes, we
simultaneously treated cells with a pan-caspase inhibitor and
PLK1-I (Figure 1b). Indeed, caspase inhibition was sufﬁcient to
signiﬁcantly increase the proportion of aneuploid WT cells, to the
same extent seen in Casp2−/− splenocytes treated with PLK1-I.
These data also show further enhanced aneuploidy in Casp2−/−
cells in the presence of a pan-caspase inhibitor, indicating that
other caspases may also play a role in limiting aneuploidy.
Interestingly, treatment with the microtubule disruptor, Taxol
also caused increased aneuploidy in Casp2−/− splenocytes
(Supplementary Figure S2c). These results indicate that Casp2
deﬁciency in primary splenocytes promotes increased aneuploidy
following mitotic disruption.
Loss of Caspase-2 impairs apoptosis of aneuploid and
multinucleated cells
Our previous studies have suggested that caspase-2 is required for
apoptosis in response to agents that disrupt cell division, such as
the microtubule stabilizing drug Taxol.16 Thus we speculated that
increased aneuploidy seen in Casp2−/− cells and tumours may be
due to the role of caspase-2 in deleting cells carrying mitotic
aberrations.5 Indeed, following treatment with PLK1-I, Casp2−/−
splenocytes were more resistant to apoptosis compared to the
WT cells (Figure 1c). Similar apoptosis resistance was apparent in
Casp2−/− splenocytes exposed to Taxol or the Eg5 inhibitor,
monastrol, which affects mitotic spindle assembly and
maintenance27 (Supplementary Figure S2d–e).
To investigate whether caspase-2-deﬁcient tumour cells were
resistant to PLK1-I-mediated cell death, we treated lymphoma
cells from Atm−/−/Casp2−/− mice (as they exhibit increased high
grade aneuploidy21), with PLK1-I over 48 h. Atm−/−/Casp2−/−
lymphoma cells similarly showed increased resistance to cell
death compared to their Atm−/− counterparts (Supplementary
Figure S3a). These ﬁndings suggest that loss of caspase-2 impedes
apoptosis of tumour cells following mitotic arrest. Since a
common cause and consequence of aneuploidy is defective
regulation and expression of SAC pathway components,10 we
examined the levels of SAC proteins in Atm−/−; Casp2−/−
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Figure 1. Caspase-2 deﬁciency enhances aneuploidy and delays
apoptosis in primary splenocytes. (a) Protocol used for time-lapse
microscopy, cell viability and aneuploidy analysis in primary
splenocytes. (b) Quantitation of metaphases showing frequencies
of diploid and aneuploid karyotypes in untreated, PLK1 inhibitor
(PLK1-I) treated and PLK1-I combined with z-VAD-fmk (pan caspase
inhibitor) treated WT (n= 4) and Casp2−/− (n= 4) splenocytes. A total
of 50 metaphase spreads were counted per mouse. P values are
indicated with **Po0.01, ***Po0.001, χ2 test. (c) Quantitation of
viable cells in WT and Casp2−/− splenocytes treated with PLK1-I for
the indicated time points, determined by trypan blue assay. Data
represented as mean± s.e.m. from four independent experiments.
P values are indicated for PLK1-I treated samples with **Po0.01.
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Cdc20, compared to Atm−/− tumours (Supplementary Figure S3b).
We also detected higher levels of these SAC proteins in
splenocytes following PLK1-I treatment (data not shown). This
may be due to either the increased proliferative capacity of these
cells21 and/or increased number of aneuploid cells in the Casp2−/−
tumour cells. Alternatively, this may indicate an intrinsic yet
uncharacterized defect due to caspase-2 deﬁciency. Together
these results suggest that caspase-2 deﬁciency enhances survival
of aneuploid cells, which harbour aberrant levels of SAC proteins
that can further contribute to enhanced mitotic progression
following caspase-2 loss.
Live imaging of aberrant mitotic arrest and multinucleation in
Caspase-2-deﬁcient cells
To examine whether caspase-2 is required for killing cells during
mitosis in vivo, we subjected untreated and PLK1-I-treated
splenocytes to live cell imaging. In control experiments there
were no apparent differences in cell morphology or cell size
between the WT and Casp2−/− splenocytes over time in culture.
Both WT and Casp2−/− splenocytes treated with PLK1-I showed
aberrant mitotic cells with altered morphology and multiple nuclei
(Figures 2a and b). However, such aberrations were more frequent
in Casp2−/− cells compared to the WT cells. A close examination of
the imaging data indicated that, while mitotic cell deaths were
apparent in both genotypes, more WT splenocytes underwent
apoptosis compared to the Casp2−/− cells (Figure 2c). These
observations were even more notable following washout of PLK1-I,
with increased survival of multinucleated and abnormally nucleated
Casp2−/− cells (Movies 1 and 2). These data suggest that the loss of
caspase-2 results in reduced mitotic cell deaths.
Acute ablation of caspase-2 enhances survival of multinucleated
cells
To further examine if acute loss of caspase-2 (as opposed to
chronic absence in cells derived from knockout mice) would result
in a similar inability to remove cells with mitotic damage, we used
small interfering RNA (siRNA) to silence CASP2 in U2OS cells
(Supplementary Figure S4) expressing a green ﬂuorescent protein
(GFP)-tagged Histone H2B construct28 and also subjected these
cells to live cell imaging (Movies 3 and 4). As observed with the
Casp2−/− splenocytes, there were signiﬁcantly less apoptotic cells
in the CASP2 siRNA transfected U2OS cells at both 24 and 48 h
following addition of PLK1-I compared to the control siRNA treated
cells (Figures 3a and b; Movies 5 and 6). While there were no
changes in morphology or cell divisions between the untreated
control cells and CASP2 depleted cells (Movies 3 and 4), following
PLK1-I washout over a 0–24 h period, there were signiﬁcantly
more aberrantly shaped multinucleated cells in the CASP2-
depleted population (Movies 7 and 8). In addition following
24–48 h of PLK1-I washout, while many control cells still died as
they attempted to undergo mitosis, CASP2 depletion resulted in
increased survival of multinucleated cells and later lead to the
accumulation of ‘giant’ cells with aberrant morphology following
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Figure 2. Loss of Caspase-2 leads to accumulation of multinucleated cells and reduced cell death in primary splenocytes following PLK1-I
treatment. (a) Representative images from live cell imaging of WT and Casp2−/− splenocytes stained with Acriﬂavine, showing cells with
multiple nuclei (arrows) and dead cells (arrow heads) at indicated time points following PLK1-I treatment. Scale bar= 50 μm. (b, c) Quantitation
of (b) multinucleated cells and (c) and dead cells from WT and Casp2−/− splenocytes at the indicated time points following PLK1-I treatment.
Data represented as mean± s.d. from three independent experiments. P values are indicated with **Po0.01, ***Po0.001.
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following CASP2-depletion, cells failed to enter metaphase but
nuclei nevertheless underwent division to give rise to live
multinucleated cells, whereas many of the control siRNA treated
cells eventually entered metaphase and died soon after (Figure 3e
and Movies 5–8). Imaging of the fate of single cells demonstrate
control siRNA treated cells dying following PLK1-I treatment over
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Figure 3. Acute knockdown of CASP2 affects cell death and promotes accumulation of cells with multiple and abnormal nuclei following PLK1-
I addition. (a) Representative images from live cell imaging of GFP-tagged histone H2B expressing U2OS cells treated with Control siRNA or
CASP2 siRNA together with PLK1-I at the indicated time points, displaying dead cells (arrows). Scale bar= 50 μm. (b) Quantitation of dead cells
in U2OS Control siRNA or CASP2 siRNA at indicated time points. Data represented as mean± s.d. from three independent experiments.
P values are indicated with **Po0.01, ***Po0.001. (c) Representative images from live cell imaging of H2B-GFP U2OS cells treated with
Control siRNA or CASP2 siRNA at the indicated time points following PLK1-I washout, displaying multinucleated cells (arrows) and cells with
abnormally large nuclei (arrow heads). Scale bar= 50 μm. (d) Quantitation of dead cells, multinucleated cells and cells with abnormal nuclei at
indicated time points following PLK1-I washout. Data represented as mean± s.d. from three independent experiments. P values are indicated
with **Po0.01, ***Po0.001. (e) Quantitation of cell cycle events following PLK1-I induced mitotic arrest. Data represented as mean± s.d. from
three independent experiments. P values are indicated with **Po0.01. (f) Clonogenic assay. Representative image of crystal violet stained
colonies in Control or CASP2 siRNA-transfected U2OS cells treated with PLK1-I (100 nM) for 48 h and cultured over 11 days. Experiment was
carried out in triplicate and the colony was deﬁned to consist of at least 50 cells. Quantitation of colony forming efﬁciency from three
independent experiments is shown. Data represent mean± s.e.m. ***Po0.001.
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24 h and following washout (Supplementary Figure S5a and b).
We did not observe any differences in the frequency of anaphase
bridge formation but demonstrate CASP2 siRNA treated cells
attempt (but fail) to undergo anaphase and are still able to survive
over 48 h post PLK1-I washout (Supplementary Figure S5b).
Together these ﬁndings suggest that CASP2 depletion can
contribute to an increased incidence of mitotic slippage and
survival of aberrant cells following PLK1-I treatment.29
To examine the long-term effect of CASP2 silencing on the
survival of PLK1-I treated multinucleated and/or aneuploid cells
we carried out a clonogenic assay and demonstrated a greater
than ﬁvefold increase in colony formation in cells depleted of
CASP2 (Figure 3f). These ﬁndings indicate that caspase-2 depletion
can enhance the clonogenic survival of aneuploid cells. Together
these experiments clearly demonstrate that both acute silencing
or ablation of caspase-2 is sufﬁcient for enhanced accumulation
and survival of cells with defective mitoses following PLK1
inhibition, which would otherwise have been deleted by
cell death.
Caspase-2 activation is required for apoptosis following mitotic
arrest
To assess caspase-2 activation following PLK1-I treatment we used
the bimolecular ﬂuorescence complementation (BiFC) assay with
full-length CASP2 gene (C320A)30 and demonstrate caspase-2
dimerization and activation following PLK1-I addition (Figure 4a).
Analysis of the kinetics of PLK1-I-mediated cell death and caspase
activation also demonstrated signiﬁcantly reduced caspase-3-like
activity in CASP2 siRNA treated U2OS cells (Figure 4b). We also
examined the cleavage dynamics of various apoptotic proteins in
U2OS cells following acute silencing of CASP2, and found that
CASP2 siRNA treatment markedly reduced the cleavage of both
caspase-3 and PARP following PLK1-I treatment (Figure 4c).
Several studies have shown that caspase-2 activation can occur
upstream of mitochondrial outer membrane permeabilization
(MOMP).12,31–33 Once active, caspase-2 cleaves Bid and this
truncated Bid (tBid) induces MOMP and apoptosis.16,34 An
examination of Bid protein levels in U2OS cells following CASP2
siRNA treatment also displayed markedly reduced cleavage
(Figure 4c). These results suggest that the increased aneuploidy
associated with the loss of caspase-2 is due to the loss of caspase
activity, which is required for Bid-mediated apoptosis.
Primary cells from Caspase-2 catalytic mutant mouse show
enhanced aneuploidy
The catalytic activity of caspase-2 has been shown to be required
to inhibit tumorigenesis and mutation of the catalytic Cysteine
residue (C320) in the caspase-2 results in the loss of its tumour
suppressor function.35 As the tumour suppressor function of
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Figure 4. Caspase-2 activation in U2OS cells during mitotic arrest is required for apoptosis. (a) Caspase-2 Venus-tagged constructs used for
BiFC assay and representative images showing caspase-2 activation at 24 h following PLK1-I treatment of U2OS cells. Scale bar= 20μm.
Quantitation of BiFC ﬂuorescence is indicated. ***Po0.001. (b) Caspase activity assays in U2OS cells treated with control or CASP2 siRNA over
the indicated time points following PLK1-I, assessed by cleavage of DEVD-AMC. Data represented as mean± s.d. from three independent
experiments. **Po0.01, ***Po0.001. (c) Immunoblot analysis of caspase-2, caspase-3, PARP and Bid cleavage in U2OS cells treated with
control or CASP2 siRNA over the indicated time points following PLK1-I.
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next examined the requirement of caspase-2 catalytic activity in
limiting aneuploidy and survival of multinucleated cells. To do this
we generated a C320 mutant mouse allele, Casp2C320S by CRISPR/
Cas9 (Figure 5). We introduced a single point mutation that
generated an XhoI site to facilitate genotyping of Casp2C320S
heterozygous (Casp2+/C320S) and homozygous (Casp2C320S/C320S)
mice (Figure 5a). DNA sequencing conﬁrmed the introduction of a
G to C point mutation resulting in a C320S amino acid substitution
(Figure 5b). Immunoblot analysis of caspase-2 protein expression
in primary splenocytes conﬁrmed expression levels of Caspase-2
mutant protein were comparable to WT (Figure 5c). We have
generated and maintained a colony of Casp2C320S mice by
intercrossing Casp2+/C320S mice over 6 months. Consistent with
our Casp2−/−mice breeding data, Casp2C320S/C320S mice are born at
normal mendelian frequency (Figure 5d) with males and females
produced at normal 1:1 ratio. Observation of these mice over
a 6-month period has not detected any overt phenotypic
differences compared to WT animals.
We next examined PLK1-I induced aneuploidy and cell death in
splenocytes from Casp2C320S/C320S mice (designated as Casp2C320S).
Consistent with our ﬁndings in Casp2−/− splenocytes, Casp2C320S
splenocytes showed signiﬁcantly greater level of aneuploidy
(Figure 6a) and increased resistance to cell death (Figure 6b)
following PLK1-I treatment. In addition, live cell imaging of
Casp2C320S splenocytes demonstrated increased numbers of
surviving multinucleate cells and reduced number of dying/dead
cells (Figures 6c–e). These are the ﬁrst ﬁndings detailing the
requirement of caspase-2 catalytic activity in limiting aneuploidy.
Importantly they conclusively demonstrate a critical role of
caspase-2 function in apoptosis of multinucleated and/or aneu-
ploid cells following mitotic stress.
DISCUSSION
This study demonstrates an important requirement for caspase-2
enzymatic activity in the apoptotic removal of mitotically aberrant
cells in response to replicative stress. We describe the generation
of Casp2C320S mutant mice and provide the ﬁrst demonstration
that caspase-2 catalytic mutation increases susceptibility to
aneuploidy. These data are consistent with an in vitro study
showing a potential function for caspase-2 in mitotic catastrophe.5
Our data further demonstrate that loss of caspase-2 promotes the
long-term survival of mitotically aberrant cells that could
potentially become tumorigenic.
Our imaging data suggest that caspase-2 activation occurs
when a speciﬁc mitotic checkpoint is breached. Interestingly,
closer analyses of real time movies show that in contrast to
WT cells, many PLK-1 inhibited Casp2−/− cells appear to exit
mitosis in prometaphase without entering metaphase. Instead,
cells enter an interphase-like state as multinucleated and/or
aneuploid cells, with enhanced ability to survive. Our ﬁndings
indicate that loss of caspase-2 affects mitosis during the
prometaphase to metaphase transition, which may include
spindle assembly or chromosome alignment to spindle. In
previous analyses using MEFs we did not detect abnormalities in
spindle formation or formation of anaphase bridges in Casp2−/−
cells during mitosis and following mitotic arrest.13 Further deﬁning
the exact mitotic checkpoint and requirement for caspase-2 would
be important in future studies.
Several studies have previously implicated caspase-2 in cell
cycle regulation and mitotic cell death.5,16,36–38 Activation of the
SAC by disrupting microtubule stability has been shown to require































































































Cross: Casp2 +/C320S x Casp2 +/C320S (n = 153)
+
Figure 5. Generation and validation of a Casp2C320S mice. (a) A representative DNA agarose gel image from genotyping of WT, Casp2+/C320S
(heterozygous) and Casp2C320S/C320S (homozygous) mice. The size of expected DNA fragments generated per genotype are indicated (bp).
(b) DNA sequencing conﬁrmation of the different genotypes as indicated. The red and blue arrows indicate the point mutation sites (G, G/C or
C) and the silent mutation site (T, T/A or A), respectively. (c) Immunoblot analysis of caspase-2 expression in splenocytes from WT and
Casp2C320S/C320S mice. β-actin is shown as loading control. (d) Genotype frequencies of the progeny from Casp2+/C320S(heterozygous)
intercrossing including observed and expected numbers of offspring. Observed and expected frequency (%) is indicated in parentheses.
Statistical comparison was performed by χ2 test.
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implicated in mitotic catastrophe, via MOMP-dependent and
p53-independent apoptosis.5,7 Our cell death data in conjunction
with our live cell imaging results demonstrate that cells treated
with PLK1-I underwent a mitotic arrest that eventually led to
mitotic death, consistent with the published deﬁnition of mitotic
catastrophe.6,39,40 Cleavage of caspase-2, caspase-3 and PARP
following PLK1-I conﬁrmed cells are undergoing apoptosis.
Silencing of caspase-2 has previously been shown to promote
cell cycle progression and mitotic slippage, resulting in asym-
metric cell division and aneuploidy.7 Our own studies have
demonstrated loss of caspase-2 enhances DNA damage, micro-
nuclei and aneuploidy in cultured cells and in tumours.13 The
increased frequency of micronuclei formation is associated with
lagging chromosomes, a likely cause of aneuploidy in these cells.
Causes of lagging chromosomes include unresolved merotelic
attachment of the kinetochore and microtubules and/or cytokin-
esis failure. Aberrant merotelic attachments can still satisfy the
SAC, so that anaphase can take place despite their presence.41,42
Merotelic attachments are often detected in cells that carry
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Figure 6. Caspase-2 catalytic cysteine mutant enhances aneuploidy. (a) Quantitation of metaphases showing frequencies of diploid and
aneuploid karyotypes in untreated and PLK1 inhibitor (PLK1-I) treated WT (n= 3) and Casp2C320S/C320S (designated as Casp2C320S) (n= 3)
splenocytes. A total of 50 metaphase spreads were counted per mouse. P values are indicated with **Po0.01, ***Po0.001, χ2 test.
(b) Quantitation of viable cells in WT and Casp2C320S splenocytes treated with PLK1-I for the indicated time points, determined by trypan blue
assay. Data represented as mean± s.e.m. from three independent experiments. P values are indicated with **Po0.01. (c) Representative
images from live cell imaging of WT and Casp2C320S splenocytes stained with Acriﬂavine, showing cells with multiple nuclei (arrows) and dead
cells (arrow heads) at the indicated time points following PLK1-I treatment. Scale bar= 50 μm. (d, e) Quantitation of multi nucleated cells
(d) and dead cells (e) at the indicated time points, following PLK1-I washout. Data represented as mean± s.d. from three independent
experiments. P values are indicated with **Po0.01, ***Po0.001.
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supernumerical centrosomes can arise from cytokinesis failure. It is
not yet known whether cells deﬁcient for caspase-2 have aberrant
centrosome number or exhibit aberrant cytokinesis, features that
may explain the occurrence of lagging chromosomes and
enhanced aneuploidy.
A defective SAC pathway can induce premature anaphase,
lagging chromosomes and micronucleus formation without
detectable mitotic arrest.43,44 It is plausible that in addition to a
role in cell death, caspase-2 has an additional role in SAC
regulation. However, many observations from Casp2-deﬁcient
mice are consistent with caspase-2 playing a role in removing
aberrant cells by apoptosis. Although Casp2-deﬁcient mice do not
spontaneously develop tumours, caspase-2 loss results in animals
that are sensitized to stress, as apparent from a mild premature
ageing phenotype.45,46 Increased oxidative stress and more
damaged cells in the liver of aged Casp2−/− mice, and the
increased genomic instability seen in tumours from EμMyc;Casp2−/−,
Atm−/−;Casp2−/−; and MMTV/c-neu; Casp2−/− mice, are all consis-
tent with a role of caspase-2 in deleting aneuploid cells by
apoptosis. Our ﬁndings that Atm−/−;Casp2−/− lymphoma cells are
more resistant to PLK1-I-mediated cell death may have important
implications for drug resistance in lymphoma treatment.47 It is
important to note that, while in most dividing cells caspase-2 is
inactive,36 our ﬁndings demonstrate that following mitotic stress,
a small population of Casp2−/− cells are resistant to apoptosis and
survive as multinucleate and aneuploid cells. Importantly, these
cells acquire an ability to survive long term in culture, an attribute
likely to contribute to enhanced cellular transformation and
tumorigenic potential.
Moreover, caspase-2 phosphorylation at Ser340 by the
mitosis-promoting kinase, cdk1–cyclin B1, maintains it in an
inactive state during mitosis and activation of caspase-2 can lead
to mitotic catastrophe.36 Consistent with these ﬁndings, our study
now shows that catalytic inactivation of caspase-2 prevents
mitotic cell death. Importantly, our data demonstrate that
caspase-2 inactivation or deﬁciency directly enhances aneuploidy.
Furthermore, caspase-2 silencing enhances clonogenic survival of
multinucleated and aneuploidy cells, suggesting a mechanism by
which loss of caspase-2 can enhance susceptibility to tumorigenic
transformation and underpins the mechanism by which caspase-2
acts as a tumour suppressor.
While other caspases, such as caspase-3 and caspase-9, have
been shown to play a role in deleting cells with damaged DNA,
micronuclei or polyploidy,48,49 our studies indicate that caspase-2
plays a dominant role in deletion of mitotically aberrant cells in
our system, since caspase-2 deﬁciency promotes aneuploidy to a
similar extent as does zVAD-mediated inhibition of caspases in
WT cells. We show that caspase-2 can limit aneuploidy via Bid-
mediated apoptosis, which further support previous ﬁndings that
caspase-2 functions upstream of MOMP, caspase-9 and caspase-3
activation.5 In addition, we know from mouse models that this
function is independent of caspase-2 interacting proteins RAIDD
and PIDD, as loss of these genes does not promote increased
aneuploidy in cells in culture or in tumours.17 Interestingly,
previous studies have shown that Bid does not appear to be
essential for DNA damage or replicative stress-induced apoptosis
or cell-cycle arrest.50 Therefore it is possible that caspase-2 may
also be able to promote apoptosis of mitotically aberrant cells in a
Bid-independent manner.
This study has established a connection between caspase-2
deﬁciency and a multi nucleated and aneuploid phenotype by
attenuation of apoptosis. This multinucleation and aneuploid
phenotype in Casp2−/− cells appears to be speciﬁc in response
disruption of the spindle assembly during mitosis. We propose
that, along with the conventional intrinsic apoptosis pathway,
caspase-2-dependent cell death augments efﬁcient removal of
cells with chromosomal defects to limit aneuploidy in vivo.
Additional studies are required to determine the factors required
for survival and proliferation of Casp2−/− aneuploid cells, and
whether these cells have enhanced tumorigenic ability and drug-
resistance. Such knowledge will be essential for understanding




Casp2−/− mice14,51 have been described previously. Animals were
maintained in speciﬁc pathogen-free conditions at the SA Pathology
Animal care facility and all animal breeding and studies were approved by
the SA Pathology/Central Northern Adelaide Health Services Animal Ethics
Committee. An equal number (between 3 and 5) of healthy adult mice
(6–8 weeks) of each genotype were randomly euthanized for primary cell
collection for each experiment. Selection of mice per genotype was not
blinded.
Generation of Casp2C320S mutant mice
CRISPR/Cas9 technology was used to generate Casp2C320S mutant mice by
SA Genome Editing Facility (Adelaide, Australia). Guide oligonucleotides
(Geneworks, Thebarton, SA, Australia) were denatured at 95 °C for 5 min
and annealed at 25 °C before being ligated into BbsI linearized px330
vector (Addgene, Cambridge, MA, USA). A template for in vitro transcrip-
tion was generated by PCR ampliﬁcation of the pX330 vector using a
forward primer containing a 5′ T7 promoter sequence and a reverse primer
that bound the TracR sequence. In vitro transcription was performed using
the HiScribe T7 In Vitro Transcription Kit (NEB, Ipswich, MA, USA) and
transcribed gRNA was puriﬁed using RNeasy Mini Kit (QIAGEN, Hilden,
Germany). The donor oligonucleotide (Integrated DNA Technologies,
Coralville, IA, USA) contained the intended point mutation as well as a
silent mutation that introduced a XhoI restriction site that was used to
screen mutant alleles. To produce Cas9 mRNA, Cas9 plasmid was linearized
using XhoI restriction enzyme (NEB) and mRNA was transcribed using
mMessage mMachine T7 Ultra Kit (Life technologies, Carlsbad, CA, USA)
followed by capping and polyadenylation. C57BL/6 females were super-
ovulated by injecting 5IU PMSG (Folligon; Intervet India, Pune, Maharashtra,
India) followed by 5IU hCG (Chorulon; Intervet India) 47.5 h later.
Superovulated females were mated to male C57BL/6 mice and fertilized
oocytes were collected from oviducts in a Hepes buffered ﬂushing and
holding medium (FHM) (Merck Millipore, Darmstadt, Germany). Oocytes
were maintained in KSOMAA (Merck Millipore) at 37 °C in 5% CO2 and were
screened for the presence of two pronuclei to indicate fertilization.
Fertilized oocytes were microinjected with a buffered solution containing
Cas9 mRNA (100 ng/μl), sgRNA (50 ng/μl) and donor oligo (100 ng/μL) in
FHM before being transferred to the oviduct of a psuedopregnant Swiss
female mouse. For genotyping of mutant mice including founder mice,
genomic DNA was extracted from postnatal day 10 tail tissue using
High Pure PCR Template Preparation Kit (ROCHE, Basel Schweiz, Switzerland).
A 497 bp fragment containing the putative mutation was ampliﬁed by PCR
and digested with XhoI restriction enzyme. Mutant alleles showed digested
products of 321 and 176 bp.






(C; point mutation target; A, silent mutation for XhoI site introduction).
Forward Guide Oligo: 5′-CACCGTTCATCCAAGCATGTCGTGG-3′
Reverse Guide Oligo: 5′-AAACCCACGACATGCTTGGATGAAC-3′
T7 PCR Oligo: 5′-TTAATACGACTCACTATAGTTCATCCAAGCATGTCGTGG-3′
The following oligonucleotides were designed for genotyping
Casp2C320S mice:
F-mC2-C320S: 5′-TTTGCCCCAACCCTTTCAGT-3′; R-mC2-C320S: 5′-CCCA
TGCATTGGGAGACACT-3′.
Cell culture
Primary cells were collected from at least three independent mice per
genotype (sample size is indicated in ﬁgure legends) and the analysis of
primary cells was performed in randomized and blinded manner. Primary
splenocytes were extracted from 6–8-week-old WT, Casp2−/− and Casp2C320
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mice. Brieﬂy, spleens were homogenized and cells ﬁltered through 40 μm
nylon mesh ﬁlter and incubated in red blood cell lysis buffer (155 mM
NH4Cl, 10 mM NaHCO3) for 5 min at room temperature. Cells were
stimulated with 10 μg/ml concanavalin A (ConA) (Sigma-Aldrich, St Louis,
MO, USA) for the ﬁrst 48 h followed by culturing in 100 U/ml recombinant
mouse IL-2, at 37 °C with 5% CO2 in DMEM media (Sigma-Aldrich)
supplemented with 10% fetal bovine serum (JRH Biosciences, Lenexa, KS,
USA), 50 μM β-mercaptoethanol (Amersham, GE Healthcare Life Sciences,
Little Chalfont, UK), non-essential amino acid mix (Sigma-Aldrich), 0.2 mM l-
glutamine (Sigma-Aldrich), 15 mM HEPES (Sigma-Aldrich) and 100 μM
penicillin/streptomycin (Sigma-Aldrich). The human osteosarcoma (U2OS)
cell line (obtained from ATCC) were maintained at 10% CO2 in DMEM
media (Sigma-Aldrich) supplemented with 10% fetal bovine serum
(JRH Biosciences), 0.2 mM l-glutamine (Sigma-Aldrich), 15 mM HEPES
(Sigma-Aldrich) and 100 μM penicillin/streptomycin (Sigma-Aldrich). Where
indicated, cells were treated with the PLK-1 inhibitor BI 2536 (50 nM)
(Axom medchem, Hanzeplein, Groningen, Netherlands), over 48 h,
Paclitaxel (100 nM) (Sigma-Aldrich) or the Eg5 inhibitor monastrol (5 μM)
(Sigma-Aldrich) over 72 h. Cell synchronization was carried out using either
a single-thymidine (for BiFC) or double-thymidine (for immunoblotting)
block (2 mM) prior to treatment with BI 2536 (100 nM). Cell viability was
determined by trypan blue dye exclusion. For population doubling times,
primary splenocytes were seeded at 1 × 106 in six-well plates at day 0. Cells
were harvested on day 6 and 8 following Con-A stimulation and number of
viable cells were estimated by trypan blue exclusion. The doubling time
was calculated as: t/n; where t=number of days for n population doublings
to occur and n=number of population doublings and was calculated as
n= log (B/A)/log 2; where A= initial cell number; B = ﬁnal cell number.
Healthy, exponentially growing cells were used in all experiments.
Live cell imaging
Freshly isolated splenocytes were imaged in 35 mm imaging dishes
(μ-Dish 35 mm, low; Ibidi, Martinsried, Germany) coated with 0.01% poly-l-
lysine (Sigma-Aldrich). Cells were either untreated or treated with BI 2536
(24 h after drug washout) and stained with 1 μM Acriﬂavine dye (Sigma-
Aldrich) prior to imaging. U2OS cells stably expressing GFP-tagged histone
H2B were generated using the pBOS-H2BGFP vector (BD, Biosciences, San
Jose, CA, USA) and were grown in μ-slide eight-well chambered dishes
(Ibidi). U2OS cells were transfected with control or CASP2 siRNA (as
described below) prior to treatment with BI 2536 and imaged for 48 h.
Following washout of BI 2536, cells were imaged for a further 48 h. Frames
were captured at 3 min intervals. All live cell imaging was repeated with at
least three independent batches of cells, and the average number of
multinucleate, ‘giant’ and dead cells per high-power ﬁeld was calculated
and statistically analysed. Live cell imaging was carried out in Cell Voyager
CV1000 Confocal Scanner (Yokogawa Electric Corporation, Tokyo, Japan).
Images were trimmed using QuickTime Player.
Knockdown of caspase-2 expression by siRNA
Caspase-2 knockdown by siRNA has been previously described.45 Two
different sets of siRNA (purchased from GenePharma, Shanghai, China)
were used to minimize any potential off-target effects, with the following
sequences; CASP2 siRNA-1 (5′-ACAGCUGUUGUUGAGCGAAdTdT-3′), CASP2
siRNA-2 (5′-GUUGUUGAGCGAAUUGUUATT-3′), control siRNA (5′-UAAGGC
UAUGAAGAGAUACTT-3′). All transfections were carried out using Trans
IT-TKO transfection reagent (Mirus, Madison, WI, USA) for 48 h according to
manufacturer’s instructions. Brieﬂy, U2OS cells (1 × 105) were seeded into
60 mm dishes in 2 ml complete medium and allowed to adhere for
16–24 h. 2.5 μl (20 μM siRNA) and 3 μl of TransIT-TKO siRNA transfection
reagent (Mirus) were diluted to 100 μl in Opti-MEM (Sigma-Aldrich) and
incubated for 15 min at room temperature. The diluted siRNA and
transfection reagent were combined and incubated for a further 15 min
at room temperature and then overlaid onto cells. After 30 h incubation at
37 °C in the transfection complexes, the media was replaced and cells were
allowed to recover for 12 h before treatment with BI 2536 (100 nM) for 48 h
and harvesting for protein analysis. Knockdown experiments were
repeated at least three times and the results statistically analysed.
Cytogenetic analysis
Preparation of chromosome spreads from untreated and BI 2536-treated
splenocytes was carried out as previously described13 by adding colcemid
(20 ng/ml), 4 h prior to harvesting cells by trypsinization, hypotonic
treatment (0.075 M KCl) and ﬁxation in fresh ice cold Carnoy’s ﬁxative
(methanol:glacial acetic acid at 3:1) for 10 min at 37 °C. Cells were
centrifuged at 1000 rpm, washed three times in Carnoy’s ﬁxative and
dropped onto wet glass slides, air dried and then placed in a 60 °C oven
overnight. Cells were stained with DAPI and chromosomes quantitated by
epiﬂuorescence microscopy (model BX51; Olympus, Tokyo, Japan) and
camera (UCMAD3/CVM300, Olympus). Cells were visualized under × 40 or
× 100 ULAPO objective lens with NA=1.5. Images were processed using
Olysia BioReport Software (Olympus) and manually merged using Adobe
Photoshop 6.0 software. Cytogenetic analysis was repeated with at least
three different batches of cells, and the average number of chromosomes
per cell per high-power ﬁeld was calculated and statistically analysed.
Chromosomal counts were carried out in a randomized and blinded
manner.
Caspase activation assays
Caspase substrate activity assays using DEVD-AMC were carried out as
previously described.52 BiFC analysis for caspase-2 activation was
performed as described previously with minor modiﬁcation.53 Brieﬂy,
full-length caspase-2 protein was fused to fragments of Venus (super
enhanced YFP) constructs to yield CASP2FL-VN (Venus fragment 1-173) and
CASP2FL-VC (Venus fragment 155-239). 2 × 10
4 U2OS cells in complete
culture medium were seeded onto 13 mm glass coverslips (Thermo Fisher
Scientiﬁc, Waltham, MA, USA) in a 24-well plate and incubated overnight at
37 °C in a 10% CO2 incubator. The next day cells were co-transfected with
150 ng of the pBiFC-HA-Capase-2 FL (C320A)-VC155 and pBiFC-HA-
Caspase-2 FL (C320A)-VN173 for BiFC and 10 ng of pDsRed-Mito (Clontech,
Mountain View, CA, USA) as a transfection reporter plasmid, using Fugene
HD reagent (Promega, Madison, WI, USA) according to the manufacturer’s
instruction. After incubation for 5 h, the medium was replaced with
complete culture medium containing z-VAD-fmk (20 μM) and cells were
incubated a further 24 h at 37 °C in a 10% CO2 incubator. Cells were then
synchronized with thymidine (2 mM; Sigma-Aldrich) and incubated for 24 h
at 37 °C in a 10% CO2 incubator. Cells were washed with pre-warmed PBS
and covered with complete culture medium containing DMSO (control) or
z-VAD-fmk (20 μM) with or without PLK1-I (BI 2536-100 nM). Cells were ﬁxed
at 24 h and 48 h after treatment. Caspase substrate activity experiments
were repeated at least three times, and results statistically analysed. CX40
epiﬂuorescence microscope (Olympus) was used for imaging BiFC and
analysis. To quantify BiFC-positive cells, total 1065 (24 h control), 394 (24 h
BI 2536), 926 (48 h control) and 391 (48 h BI 2536) cells were counted in
three different areas in four independent experiments. Statistical analysis
was carried out in GraphPad Prism, Version 6.05 (GraphPad, GraphPad
Software Inc., La Jolla, CA, USA).
Immunoblotting
Protein lysates were prepared from primary splenocytes or tumour tissue
by cell lysis and/or homogenization in RIPA buffer [25 mM Tris/HCl pH 7.4,
150 mM NaCl, 1% nonyl-phenoxylpolyethoxylethanol (NP-40), 1% sodium
deoxycholate, 0.1% sodium dodecyl sulphate (SDS)], in the presence of
protease/phosphatase inhibitor cocktail (Thermo Fisher Scientiﬁc). Homo-
genates were treated by three freeze/thaw cycles in liquid nitrogen,
clariﬁed by centrifugation at 13.2 K rpm and protein concentration
determined by BCA quantitation (Bio-Rad, Hercules, CA, USA). 30 or
50 μg of lysates were resolved on 4–20% Mini-PROTEAN TGX gel (Bio-Rad),
12or 15% SDS-PAGE gel as appropriate and transferred onto PVDF
membrane and probed for the speciﬁed antibody for 2 h at room
temperature or overnight at 4 °C. Secondary antibodies, conjugated with
horseradish peroxidase, alkaline phosphatase or Cy5 (Millipore/GE
Healthcare, Chicago, IL, USA), were incubated at room temperature for
2 h. Proteins were visualized using ECF or ECL (Millipore/GE Healthcare).
The following antibodies were used: caspase-2 (clone 11B4), PARP (#9542),
caspase-3 (#9662), Mad2 (#4636) (Cell Signalling Technology, Danvers, MA,
USA), cyclin B1 (#sc-245) (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
β-actin (#A5316), Bub3 (#B7811) (Sigma-Aldrich), Bid (#AF846) (R&D
Systems, Minneapolis, MN, USA) and Cdc20 (#ab183479) (Abcam,
Cambridge, MA, USA). Immunoblotting experiments were repeated at
least three times, and the results were statistically analysed.
Clonogenic assays
Clonogenic assays were carried out as previously described.54 Brieﬂy, U2OS
cells were seeded at 1 × 105 cells in a 60 mm dish. Cells were transfected
with either control or CASP2 siRNA for 48 h followed by treatment with
PLK1-I (100 nM) for a further 48 h. Cells were then harvested and reseeded
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at a density of 800 viable cells per well in a six-well plate, in triplicate. After
culturing 11 days, the colonies were stained with 6% glutaraldehyde (Ajax
Finechem, NSW, Australia) and 0.5% crystal violet (Sigma-Aldrich) and
counted using a stereomicroscope (Nikon, Tokyo, Japan). A colony was
deﬁned as consisting of at least 50 cells and experiments were repeated at
least three times for statistical analysis. Colony forming efﬁciency
(%) = (total number of colonies/number plated cells) 100%.
Flow cytometry
Splenocytes (2 × 106) either untreated or treated with BI 2536 (50 nM) were
ﬁxed in 70% v/v ethanol and stored at − 20 °C. Fixed cells were rehydrated
by washing 2–3 times in PBS with centrifugation at 500×g for 5 min.
Cells were then permeabilized with 0.25% v/v Triton X-100/PBS for 10 min
at room temperature and then incubated in staining solution containing
40 μg/mL RNase A (Roche) and 25 μg/ml propidum iodide (Sigma-Aldrich),
for at least 3 h at room temperature. Cells were stored at 4 °C then
analysed on an FC500 ﬂow cytometer (Beckman Coulter, Brea, CA, USA). At
least 50 000 events were recorded per sample and results were statistically
analysed. Cellular debris and doublets were excluded from the analysis
based on non-linearity on a doublet discrimination plot. Data analysis was
performed using Multicycle AV on FCS Express Flow Cytometry Research
Edition Version 4 (DeNovo Software, Glendale, CA, USA).
Statistical analysis of data
Statistical analysis was carried out in GraphPad Prism, Version 6.05
(GraphPad, GraphPad Software Inc) or using Microsoft Excel 2010.
A two-sided Student’s t-test was used to estimate differences between
data groups, unless otherwise stated. Data are expressed as mean± s.e.m.
P-valueso0.05 were considered as statistically signiﬁcant. The sample
sizes were determined by power analyses, based on variation shown in our
previous experiments and predicted effect sizes considered to be
biological signiﬁcant. No data were excluded from any analyses and all
replicates are true biological replicates. The statistical test used and the
sample sizes for individual analyses are provided within the ﬁgure legends.
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